Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9291119 | 0.83 | METAP1 (0.50) | METAP1NPC1SMN1; SMN2CYP17A1MEN1 | |
| SCHEMBL14510093 | 0.82 | METAP1 (0.49) | METAP1NPC1SMN1; SMN2CA12CA1 | |
| SCHEMBL11564693 | 0.81 | METAP1 (0.48) | METAP1NPC1RAB9ASMN1; SMN2CYP17A1 | |
| SCHEMBL395773 | 0.81 | METAP1 (0.48) | METAP1NPC1SMN1; SMN2CYP17A1CA12 | |
| SCHEMBL3134543 | 0.80 | BCL2 (0.43) | METAP1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL7461547 | 0.79 | METAP1 (0.47) | METAP1NPC1CYP17A1CA12CA1 | |
| SCHEMBL7457637 | 0.79 | NPSR1 (0.50) | METAP1NPC1SMN1; SMN2RXFP1LMNA | |
| SCHEMBL429230 | 0.79 | PTPN2 (0.57) | METAP1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL399916 | 0.79 | METAP1 (0.43) | METAP1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL6242277 | 0.78 | METAP1 (0.46) | METAP1NPC1SMN1; SMN2CYP17A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735114-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | Masarykova Univerzita (CZ) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025002491-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | MASARYKOVA UNIVERZITA (CZ) | 2025-01-02 | — | — | WO | disclosed |
| EP-4483954-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | Masarykova Univerzita (CZ) | 2025-01-01 | — | — | EP | disclosed |
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| WO-2024097855-A2 | IDENTIFICATION OF SMALL MOLECULES THAT RECRUIT AND ACTIVATE RNASE L | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023085415-A1 | COMPOUND, ANGIOTENSIN-II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2023-05-19 | — | — | WO | disclosed |
| US-9255096-B1 | Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors | ALLERGAN, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255096-B1 | Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors | ALLERGAN, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-7696221-B2 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFκB inhibitors | WYETH LLC (US) | 2010-04-13 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| WO-2009102462-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1706395-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060154875-A1 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors | WYETH (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | METAP1 1933/4885NPC1 4256/4885RAB9A 1894/4885 |
| US-20060154875-A1 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors | NFKBIA, IKBKB, IKBKE | METAP1 3395/4885NPC1 2210/4885RAB9A 2058/4885 |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | METAP1 1933/4885NPC1 4256/4885RAB9A 1894/4885 |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | HRH2, HRH1, TSLP | METAP1 873/4885NPC1 3082/4885RAB9A 3818/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | METAP1 2790/4885NPC1 1271/4885RAB9A 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.